NCT02838693View on ClinicalTrials.gov

Assessing Progression to Type-2 Diabetes (APT-2D): A Prospective Cohort Study Expanded From BRITE-SPOT (Bio-bank and Registry for StratIfication and Targeted intErventions in the Spectrum Of Type 2 Diabetes)

UnknownOBSERVATIONAL
Enrollment

2,300

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

September 30, 2021

Study Completion Date

December 31, 2021

Conditions
Pre-diabetesDiabetes
Interventions
PROCEDURE

Not applicable. This is an observational study.

Not applicable. This is an observational study.

Trial Locations (1)

119074

RECRUITING

National University Hospital, Singapore

Sponsors

Lead Sponsor

Medicine

Collaborators (1)

Janssen Pharmaceuticals
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

collaborator

National Medical Research Council (NMRC), Singapore

OTHER_GOV

lead

Medicine

OTHER

NCT02838693 - Assessing Progression to Type-2 Diabetes (APT-2D): A Prospective Cohort Study Expanded From BRITE-SPOT (Bio-bank and Registry for StratIfication and Targeted intErventions in the Spectrum Of Type 2 Diabetes) | Biotech Hunter | Biotech Hunter